• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

npwt

  1. Medela lays off all in wound division

    Entire department cut down to basically a few remote hybrid reps. With some feet on the street “business managers”, former regional managers who were demoted, to visit prospects and handle proposals. Everything will be outsourced to 1099’s from there.
  2. Medela Wound Reps all let go

    Entire department cut down to basically a few remote hybrid reps. With some feet on the street “business managers”, former regional managers who were demoted, to visit prospects and handle proposals. Everything will be outsourced to 1099’s from there.
  3. Get in there, KCI

    Wherever Medela was a threat and breathing down your neck’s with drop their pants pricing, which granted, was a small footprint only nationally, take note that they let go of their entire negative pressure sales force yesterday. Save for four reps nationwide who will act in a hybrid role feeling...
  4. Bye, bye Negative Pressure Sales Team

    Medela cut the entire negative pressure sales force yesterday, save for four reps nationwide who will act in a hybrid role feeling out opportunities. Managers basically demoted to glorified remote rep roles, since they have no direct reports and are lucky to still be retained at all. Marketing...
  5. Medela US - Horrible Company

    Is it just me or has Medela become a company it's founding father would cringe to know about. Ollie is probably up in heaven wondering where he went wrong! The company is in decline and will continue to be until Leadership is replaced. MG is the worst of the lot. Maybe because she has...